Valuation : Genome & Company

Market Cap 200B 145M 125M 117M 107M 201M 13.84B 202M 1.39B 541M 6.98B 544M 532M 23.16B P/E 2024
-4.17x
P/E 2025 -33.5x
Enterprise Value 182B 132M 114M 106M 97.21M 183M 12.6B 184M 1.26B 493M 6.36B 495M 484M 21.09B EV / Sales 2024
1.31x
EV / Sales 2025 8.97x
Free-Float
85.14%
Yield 2024 *
-
Yield 2025 -
Apr. 13 Genome & Company announced that it has received KRW 6.99999414 billion in funding CI
Apr. 02 Genome & Company announced that it expects to receive KRW 6.99999414 billion in funding CI
Mar. 12 Genome & Company announced that it has received KRW 29.99998254 billion in funding from DongKoo Bio & Pharma Co., Ltd. CI
25-09-21 Genome & Company(KOSDAQ:A314130) dropped from S&P Global BMI Index CI
25-08-20 An undisclosed buyer agreed to acquire 40.12% stake in List Biotherapeutics, Inc. from Genome & Company for $19.1 million. CI
25-07-10 Genome & Company announced that it has received KRW 25.7890592 billion in funding CI
25-04-27 Genome & Company announced that it has received KRW 27.066097613 billion in funding from a group of investors CI
25-04-23 Genome & Company announced that it expects to receive KRW 27.066097613 billion in funding from a group of investors CI
25-04-23 Genome & Company announced that it expects to receive KRW 27.06426965 billion in funding CI
25-04-23 Genome & Company agreed to acquire an additional 28.64% stake in List Biotherapeutics, Inc. from a group of shareholders for KRW 27.07 billion. CI
24-07-18 Genome & Company announced that it has received KRW 4.5 billion in funding from Paratus New Normal CB Private Equity Fund Co., Ltd, Susung Asset Management Co., Ltd. CI
24-07-16 Genome & Company announced that it expects to receive KRW 4.5 billion in funding from Paratus New Normal CB Private Equity Fund Co., Ltd, Susung Asset Management Co., Ltd. CI
24-01-24 Genome & Company Announces Positive Topline Results from Phase 2 Clinical Trial of Combination of GEN-001 and Bavencio®? for the Treatment of Gastric Cancer Poster Presented at ASCO GI CI
1 day-4.27%
1 week-9.27%
Current month+16.31%
1 month+23.06%
3 months-37.66%
6 months-40.02%
Current year-44.55%
1 week 3,800
Extreme 3800
4,365
1 month 3,060
Extreme 3060
4,720
Current year 2,975
Extreme 2975
10,180
1 year 2,440
Extreme 2440
10,180
3 years 2,170
Extreme 2170
10,180
5 years 2,170
Extreme 2170
28,800
10 years 2,170
Extreme 2170
47,500
Manager TitleAgeSince
Chief Executive Officer 53 2015-09-23
Chief Executive Officer 55 2015-09-23
Director TitleAgeSince
Director/Board Member 55 2015-09-23
Director/Board Member 53 2015-09-23
Director/Board Member 62 -
Date Insider Type Main position Quantity % Market Cap.
5/9/25 Don

Chief Executive Officer

100,000 0.3217%
5/9/25 Free

Director

40,000 0.1287%
5/9/25 Free

Public Communications Manager

50,000 0.1608%
Change 5-day change 1-year change 3-year change Capi.($)
-4.27%-9.27%+49.02%-52.90% 145M
-0.78%-1.42%+2.96%+21.65% 50.47B
-6.00%-0.75%+447.48%+535.14% 44.56B
-0.24%+0.74%+37.18%+16.26% 43.08B
-1.55%-2.07%+19.83%+71.70% 41.7B
-0.31%-0.83%+19.47%+48.24% 33.21B
-1.79%-3.24%+26.32%+125.06% 16.77B
-0.58%-2.12% - - 16.28B
-0.88%-0.66%+11.63%+27.62% 14.58B
-1.66%-1.25%+78.49%+42.97% 13.92B
Average -1.81%-1.95%+76.93%+92.86% 27.47B
Weighted average by Cap. -1.70%-1.06%+96.25%+128.93%

Financials

2024 2025
Net sales 27.74B 20.13M 17.35M 16.26M 14.85M 27.97M 1.92B 28.06M 193M 75.29M 971M 75.58M 73.94M 3.22B 24.59B 17.84M 15.37M 14.41M 13.16M 24.79M 1.7B 24.86M 171M 66.72M 861M 66.98M 65.52M 2.85B
Net income -20.11B -14.59M -12.57M -11.79M -10.76M -20.28M -1.39B -20.34M -140M -54.58M -704M -54.79M -53.6M -2.33B -6.43B -4.66M -4.02M -3.77M -3.44M -6.48M -446M -6.5M -44.71M -17.44M -225M -17.51M -17.13M -746M
Net Debt -48.91B -35.48M -30.58M -28.67M -26.17M -49.3M -3.39B -49.46M -340M -133M -1.71B -133M -130M -5.68B -17.86B -12.96M -11.17M -10.47M -9.56M -18.01M -1.24B -18.06M -124M -48.47M -625M -48.66M -47.6M -2.07B
Logo Genome & Company
Genome&Company Inc is a Korea-based company primarily engaged in the business of new drug development. The Company operates its business through three segments. The New Drug Development segment primarily develops anticancer drugs and microbiome medicines. The Contract Development and Manufacturing Organization (CDMO) segment primarily provides microbiome therapeutic contract development and manufacturing organization services. The Consumer segment primarily engages in the microbiome cosmetics and health functional food business.
Employees
-
Date Price Change Volume
26-08-28 ₩3,815.00 -4.27% 293,314
26-08-27 ₩3,985.00 -1.48% 188,452
26-08-26 ₩4,045.00 -0.74% 328,849
26-08-25 ₩4,075.00 -3.89% 283,749
26-08-24 ₩4,240.00 +0.83% 208,829
  1. Stock Market
  2. Stocks
  3. A314130 Stock